G-CSF Administration Is Associated with Worse Treatment Response and Survival after CAR T-Cell TherapyPoorva Bindal, Jon Arnason, Pavania Elavalakanar et al.|Blood|2022Cited by 4
Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)–Negative complete responses in Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR T-cell therapiesTae‐Min Kim, Seok‐Goo Cho, Sumana Devata et al.|Blood|2025Cited by 2
Corticosteroids, Tocilizumab or Filgrastim Do Not Impact the Efficacy of CAR T-Cell Therapy with 4- 1BB Costimulatory DomainPoorva Bindal, Jon Arnason, Caitlin A. Trottier et al.|Transplantation and Cellular Therapy|2022Cited by 0